March 2026 Research Update

This month added an early but clear signal that blocking a specific step in oxalate production can reduce oxalate-related kidney damage in a primary hyperoxaluria type 2 (PH2) animal model. In Grhpr knockout mice (used to model PH2), the drug N-propargylglycine (N-PPG) lowered urine oxalate, prevented calcium oxalate stone formation, and reduced signs of kidney tubule injury compared with untreated mice. The results also linked these changes to broader health outcomes in the mice, including better weight and longer survival. [1]

In this mouse study, N-PPG was used to inhibit Hypdh/Prodh2, an enzyme pathway the authors aimed to target to reduce oxalate. The researchers reported improvements within weeks, and in a longer follow-up (24 weeks) they reported sustained suppression of hyperoxaluria along with preserved kidney function markers. The study also reported the treatment was well tolerated in this animal model. [1]

For patients and caregivers, this is early research that mainly matters for what it suggests could be possible in the future, not for what is available now. The study helps clarify that, at least in a PH2 mouse model, reducing oxalate production upstream may translate into fewer calcium oxalate deposits and less kidney injury. What remains unknown is whether this approach is safe and effective in people with PH2, and what dose or long-term effects would look like outside a controlled animal setting. [1]

This month also highlighted that serious oxalate-related kidney injury is not limited to primary hyperoxaluria, and can occur when the gut absorbs too much oxalate. A case report described a person with chronic pancreatitis and exocrine pancreatic insufficiency who developed calcium oxalate crystal buildup in the kidneys and worsening kidney failure. The report connects malabsorption problems in the intestine with higher oxalate levels in the body and crystal-related kidney damage. [2]

In this single patient, testing showed a very elevated plasma oxalate level and a kidney biopsy showed calcium oxalate crystals inside kidney tubules with inflammation and acute tubular injury. The person later progressed to dialysis-dependent end-stage kidney disease, and the report notes there are no strong clinical studies testing corticosteroids for this condition. Because this is one case, it cannot show what usually happens or what treatments work, but it provides a concrete example of how oxalate can injure kidneys in secondary (non-genetic) settings. [2]

For the primary hyperoxaluria community, this case does not change what is known about genetic PH, but it can help explain why doctors sometimes consider oxalate problems even in people without PH. It matters most as background understanding: high oxalate and calcium oxalate crystals can be seen in different medical situations, and the cause (genetic versus gut-related absorption) affects what questions get asked and what gets measured. What remains uncertain from this report is whether anti-inflammatory treatments like steroids help or harm in secondary oxalate nephropathy, since the evidence here is limited to one patient experience and the authors note a lack of broader studies. [2]